VEGF/Neuropilin Signaling in Cancer Stem Cells
| dc.contributor.author | Mercurio, Arthur M. | |
| dc.date | 2022-08-11T08:09:52.000 | |
| dc.date.accessioned | 2022-08-23T16:46:42Z | |
| dc.date.available | 2022-08-23T16:46:42Z | |
| dc.date.issued | 2019-01-23 | |
| dc.date.submitted | 2019-03-12 | |
| dc.identifier.citation | <p>Int J Mol Sci. 2019 Jan 23;20(3):490. pii: ijms20030490. doi: 10.3390/ijms20030490. <a href="https://doi.org/10.3390/ijms20030490">Link to article on publisher's site</a></p> | |
| dc.identifier.issn | 1422-0067 (Linking) | |
| dc.identifier.doi | 10.3390/ijms20030490 | |
| dc.identifier.pmid | 30678134 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.14038/40932 | |
| dc.description.abstract | The function of vascular endothelial growth factor (VEGF) in cancer extends beyond angiogenesis and vascular permeability. Specifically, VEGF-mediated signaling occurs in tumor cells and this signaling contributes to key aspects of tumorigenesis including the self-renewal and survival of cancer stem cells (CSCs). In addition to VEGF receptor tyrosine kinases, the neuropilins (NRPs) are critical for mediating the effects of VEGF on CSCs, primarily because of their ability to impact the function of growth factor receptors and integrins. VEGF/NRP signaling can regulate the expression and function of key molecules that have been implicated in CSC function including Rho family guanosine triphosphatases (GTPases) and transcription factors. The VEGF/NRP signaling axis is a prime target for therapy because it can confer resistance to standard chemotherapy, which is ineffective against most CSCs. Indeed, several studies have shown that targeting either NRP1 or NRP2 can inhibit tumor initiation and decrease resistance to other therapies. | |
| dc.language.iso | en_US | |
| dc.relation | <p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=30678134&dopt=Abstract">Link to Article in PubMed</a></p> | |
| dc.rights | © 2019 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). | |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
| dc.subject | VEGF | |
| dc.subject | cancer stem cell | |
| dc.subject | neuropilin | |
| dc.subject | Amino Acids, Peptides, and Proteins | |
| dc.subject | Cancer Biology | |
| dc.subject | Cell Biology | |
| dc.subject | Cells | |
| dc.subject | Enzymes and Coenzymes | |
| dc.subject | Neoplasms | |
| dc.title | VEGF/Neuropilin Signaling in Cancer Stem Cells | |
| dc.type | Journal Article | |
| dc.source.journaltitle | International journal of molecular sciences | |
| dc.source.volume | 20 | |
| dc.source.issue | 3 | |
| dc.identifier.legacyfulltext | https://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=4745&context=oapubs&unstamped=1 | |
| dc.identifier.legacycoverpage | https://escholarship.umassmed.edu/oapubs/3731 | |
| dc.identifier.contextkey | 14008330 | |
| refterms.dateFOA | 2022-08-23T16:46:42Z | |
| html.description.abstract | <p>The function of vascular endothelial growth factor (VEGF) in cancer extends beyond angiogenesis and vascular permeability. Specifically, VEGF-mediated signaling occurs in tumor cells and this signaling contributes to key aspects of tumorigenesis including the self-renewal and survival of cancer stem cells (CSCs). In addition to VEGF receptor tyrosine kinases, the neuropilins (NRPs) are critical for mediating the effects of VEGF on CSCs, primarily because of their ability to impact the function of growth factor receptors and integrins. VEGF/NRP signaling can regulate the expression and function of key molecules that have been implicated in CSC function including Rho family guanosine triphosphatases (GTPases) and transcription factors. The VEGF/NRP signaling axis is a prime target for therapy because it can confer resistance to standard chemotherapy, which is ineffective against most CSCs. Indeed, several studies have shown that targeting either NRP1 or NRP2 can inhibit tumor initiation and decrease resistance to other therapies.</p> | |
| dc.identifier.submissionpath | oapubs/3731 | |
| dc.contributor.department | Department of Molecular, Cell and Cancer Biology | |
| dc.source.pages | 490 |

